Phase 3 Clinical Trials With Primary Completion Dates in August 2016
This is a list of Phase 3 trials with primary completion dates in August 2016 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Symbol||Company||Primary Completion Date||Phase||NCT ID||Title|
|ATRS||Antares Pharma, Inc.||2016-08-01||Phase 3||NCT02504541||Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism (STEADY)|
|CTIC||CTI BioPharma Corp.||2016-08-01||Phase 3||NCT02055781||Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia|
|CVM||Cel-Sci Corporation||2016-08-01||Phase 3||NCT01265849||Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity|
|INNL||Innocoll Holdings||2016-08-01||Phase 3||NCT02427802||Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers|
|ITCI||Intra-Cellular Therapies Inc.||2016-08-01||Phase 3||NCT02469155||A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment|
|MNK||Mallinckrodt plc||2016-08-01||Phase 3||NCT01520545||Safety Study of 3 mg/mL Baclofen Injection (Intrathecal) Using A Programmable Pump|
|TARO||Taro Pharmaceutical Industries Ltd.||2016-08-01||Phase 3||NCT02618759||Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis|
|TBPH||Theravance Biopharma, Inc.||2016-08-01||Phase 3||NCT02512510||Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)|
|TBPH||Theravance Biopharma, Inc.||2016-08-01||Phase 3||NCT02459080||Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)|